Vitiligo, New Treatment and Serum s100B

Inclusion Criteria: * active generalized vitiligo patients with body surface area involved \>5% excluding hands and feet * no systemic treatment for vitiligo for the last 3 months or topical treatment received for the last 4 weeks. Exclusion Criteria: * acrofacial, acral, segmental or mucosal vitiligo * patients on another immunosuppressive agent * patients have other skin conditions (psoriasis, SLE, alopecia areata) that would interfere with evaluations of the effect of study medication on vitiligo. * patients who suffered from systemic diseases affecting S100B (e.g. Subarachnoid hemorrhage, Alzheimer disease and inflammatory diseases) or from other dermatological diseases affecting S100B level (e.g. malignant melanoma) * Patients immunocompromised, uncontrolled arterial hypertension, clinically serious viral, bacterial, fungal, or parasitic infection, anemia, history of thromboembolic event, cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, lymphoproliferative disease, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness. * Pregnancy and lactation.